RNA silencing

From Wikipedia, the free encyclopedia
Jump to: navigation, search

RNA silencing (associated with the concept of post-transcriptional gene silencing (PTGS) or RNA interference) refers to a family of gene silencing effects by which the expression of one or more genes is downregulated or entirely suppressed by small non-coding RNAs. It may also refer to the introduction of a synthetic antisense RNA molecule used in scientific experiments on gene expression. RNA silencing may also be defined as sequence-specific regulation of gene expression triggered by double-stranded RNA (dsRNA).[1] RNA silencing mechanisms are highly conserved in most eukaryotes.[2] The most common and well-studied example is RNA interference (RNAi), in which endogenously expressed microRNA (miRNA) or exogenously derived small interfering RNA (siRNA) induces the degradation of complementary messenger RNA. Other classes of small RNA have been identified, including piwi-interacting RNA (piRNA) and its subspecies repeat associated small interfering RNA (rasiRNA).[3]

Background[edit]

RNA silencing describes several mechanistically related pathways which are involved in controlling and regulating gene expression.[4][5][6] RNA silencing pathways are associated with the regulatory activity of small non-coding RNAs (approximately 20–30 nucleotides in length) that function as factors involved in inactivating homologous sequences, promoting endonuclease activity, translational arrest, and/or chromatic or DNA modification.[7][8][9] In the context in which the phenomenon was first studied, small RNA was found to play an important role in defending plants against viruses. For example, these studies demonstrated that enzymes detect double-stranded RNA (dsRNA) not normally found in cells and digest it into small pieces that are not able to cause disease.[10][11][12][13][14]

While some functions of RNA silencing and its machinery are understood, many are not. For example, RNA silencing has been shown to be important in the regulation of development and in the control of transposition events.[15] RNA silencing has been shown to play a role in antiviral protection in plants as well as insects.[16] Also in yeast, RNA silencing has been shown to maintain heterochromatin structure.[17] However, the varied and nuanced role of RNA silencing in the regulation of gene expression remains an ongoing scientific inquiry. A range of diverse functions have been proposed for a growing number of characterized small RNA sequences—e.g., regulation of developmental, neuronal cell fate, cell death, proliferation, fat storage, haematopoietic cell fate, insulin secretion.[18]

RNA silencing functions by repressing translation or by cleaving messenger RNA (mRNA), depending on the amount of complementarity of base-pairing. RNA has been largely investigated within its role as an intermediary in the translation of genes into proteins.[19] More active regulatory functions, however, only began to be addressed by researchers beginning in the late-1990s.[20] The landmark study providing an understanding of the first identified mechanism was published in 1998 by Fire et al.,[1] demonstrating that double-stranded RNA could act as a trigger for gene silencing.[20] Since then, various other classes of RNA silencing have been identified and characterized.[4] Presently, the therapeutic potential of these discoveries is being explored, for example, in the context of targeted gene therapy.[21][22]

While RNA silencing is an evolving class of mechanisms, a common theme is the fundamental relationship between small RNAs and gene expression.[8] It has also been observed that the major RNA silencing pathways currently identified have mechanisms of action which may involve both post-transcriptional gene silencing (PTGS)[23] as well as chromatin-dependent gene silencing (CDGS) pathways.[4] CDGS involves the assembly of small RNA complexes on nascent transcripts and is regarded as encompassing mechanisms of action which implicate transcriptional gene silencing (TGS) and co-transcriptional gene silencing (CTGS) events.[24] This is significant at least because the evidence suggests that small RNAs play a role in the modulation of chromatin structure and TGS.[25][26]

Despite early focus in the literature on RNA interference (RNAi) as a core mechanism which occurs at the level of messenger RNA (mRNA) translation, others have since been identified in the broader family of conserved RNA silencing pathways acting at the DNA and chromatin level.[27] RNA silencing refers to the silencing activity of a range of small RNAs and is generally regarded as a broader category than RNAi. While the terms have sometimes been used interchangeably in the literature, RNAi is generally regarded as a branch of RNA silencing. To the extent it is useful to craft a distinction between these related concepts, RNA silencing may be thought of as referring to the broader scheme of small RNA related controls involved in gene expression and the protection of the genome against mobile repetitive DNA sequences, retroelements, and transposons to the extent that these can induce mutations.[28] The molecular mechanisms for RNA silencing were initially studied in plants[12] but have since broadened to cover a variety of subjects, from fungi to mammals, providing strong evidence that these pathways are highly conserved.[29]

At least three primary classes of small RNA have currently been identified, namely: small interfering RNA (siRNA), microRNA (miRNA), and piwi-interacting RNA (piRNA).

small interfering RNA (siRNA)[edit]

siRNAs act in the nucleus and the cytoplasm and are involved in RNAi as well as CDGS.[4] siRNAs come from long dsRNA precursors derived from a variety of single-stranded RNA (ssRNA) precursors, such as sense and antisense RNAs. siRNAs also come from hairpin RNAs derived from transcription of inverted repeat regions. siRNAs may also arise enzymatically from non-coding RNA precursors.[30] The volume of literature on siRNA within the framework of RNAi is extensive.

microRNA (miRNA)[edit]

The majority of miRNAs act in the cytoplasm and mediate mRNA degradation or translational arrest.[31] However, some plant miRNAs have been shown to act directly to promote DNA methylation.[32] miRNAs come from hairpin precursors generated by the RNaseIII enzymes Drosha and Dicer.[33] Both miRNA and siRNA form either the RNA-induced silencing complex (RISC) or the nuclear form of RISC known as RNA-induced transcriptional silencing complex (RITS).[34] The volume of literature on miRNA within the framework of RNAi is extensive.

piwi-interacting RNA (piRNA)[edit]

piRNAs represent the largest class of small non-coding RNA molecules expressed in animal cells, deriving from a large variety of sources, including repetitive DNA and transposons.[35] However, the biogenesis of piRNAs is also the least well understood.[36] piRNAs appear to act both at the post-transcriptional and chromatin levels. They are distinct from miRNA due to at least an increase in terms of size and complexity. Repeat associated small interfering RNA (rasiRNAs) are considered to be a subspecies of piRNA.[3]

Mechanism[edit]

MiRNA processing

The most basic mechanistic flow for RNA Silencing is as follows: (For a more detailed explanation of the mechanism, refer to the RNAi:Cellular mechanism article.)

1: RNA with inverted repeats hairpin/panhandle constructs --> 2: dsRNA --> 3: miRNAs/siRNAs --> 4: RISC --> 5: Destruction of target mRNA

  1. It has been discovered that the best precursor to good RNA silencing is to have single stranded antisense RNA with inverted repeats which, in turn, build small hairpin RNA and panhandle constructs.[6] The hairpin or panhandle constructs exist so that the RNA can remain independent and not anneal with other RNA strands.
  2. These small hairpin RNAs and/or panhandles then get transported from the nucleus to the cytosol through the nuclear export receptor called exportin-5, and then get transformed into a dsRNA, a double stranded RNA, which, like DNA, is a double stranded series of nucleotides. If the mechanism didn't use dsRNAs, but only single strands, there would be a higher chance for it to hybridize to other "good" mRNAs. As a double strand, it can be kept on call for when it is needed.
  3. The dsRNA then gets cut up by a Dicer into small (21-28 nt = nucleotides long) strands of miRNAs (microRNAs) or siRNAs (short interfering RNAs.) A Dicer is an endoribonuclease RNase, which is a complex of a protein mixed with strand(s) of RNA.
  4. Lastly, the double stranded miRNAs/siRNAs separate into single strands; the antisense RNA strand of the two will combine with another endoribonuclease enzyme complex called RISC (RNA-induced silencing complex), which includes the catalytic component Argonaute, and will guide the RISC to break up the "perfectly complementary" target mRNA or viral genomic RNA so that it can be destroyed.[14][6]
  5. It means that based on a short sequence specific area, a corresponding mRNA will be cut. To make sure, it will be cut in many other places as well. (If the mechanism only worked with a long stretch, then there would be higher chance that it would not have time to match to its complementary long mRNA.) It has also been shown that the repeated-associated short interference RNAs (rasiRNA) have a role in guiding chromatin modification.[14]

For an animated explanation of the mechanism of RNAi by Nature Reviews, see the External Links section below.

Biological Functions[edit]

Immunity against viruses or transposons[edit]

RNA silencing is the mechanism that our cells (and cells from all kingdom (biology)) use to fight RNA viruses and transposons (which originate from our own cells as well as from other vehicles.) [14] In the case of RNA viruses, these get destroyed immediately by the mechanism cited above. In the case of transposons, it's a little more indirect. Since transposons are located in different parts of the genome, the different transcriptions from the different promoters produce complementary mRNAs that can hybridize with each other. When this happens, the RNAi machinery goes into action, debilitating the mRNAs of the proteins that would be required to move the transposons themselves.[37]

Down-regulation of genes[edit]

For a detailed explanation of the down-regulation of genes, see RNAi:downregulation of genes

Up-regulation of genes[edit]

For a detailed explanation of the up-regulation of genes, see RNAi:upregulation of genes

RNA silencing also gets regulated[edit]

The same way that RNA silencing regulates downstream target mRNAs, RNA silencing itself is regulated. For example, silencing signals get spread between cells by a group of enzymes called RdRPs (RNA-dependent RNA polymerases) or RDRs.[14]

Practical Applications[edit]

Growing understanding of small RNA gene-silencing mechanisms involving dsRNA-mediated sequence-specific mRNA degradation has directly impacted the fields of functional genomics, biomedicine, and experimental biology. The following section describes various applications involving the effects of RNA silencing. These include uses in biotechnology, therapeutics, and laboratory research. Bioinformatics techniques are also being applied to identify and characterize large numbers of small RNAs and their targets.

Biotechnology[edit]

Artificial introduction of long dsRNAs or siRNAs has been adopted as a tool to inactivate gene expression, both in cultured cells and in living organisms.[14] Structural and functional resolution of small RNAs as the effectors of RNA silencing has had a direct impact on experimental biology. For example, dsRNA may be synthesized to have a specific sequence complementary to a gene of interest. Once introduced into a cell or biological system, it is recognized as exogenous genetic material and activates the corresponding RNA silencing pathway. This mechanism can be used to effect decreases in gene expression with respect to the target, useful for investigating loss of function for genes relative to a phenotype. That is, studying the phenotypic and/or physiologic effects of expression decreases can reveal the role of a gene product. The observable effects can be nuanced, such that some methods can distinguish between “knockdown” (decrease expression) and “knockout” (eliminate expression) of a gene.[38] RNA interference technologies have been noted recently as one of the most widely utilized techniques in functional genomics.[39] Screens developed using small RNAs have been used to identify genes involved in fundamental processes such as cell division, apoptosis and fat regulation.

Biomedicine[edit]

Since at least the mid-2000s, there has been intensifying interest in developing short interfering RNAs for biomedical and therapeutic applications.[40] Bolstering this interest is a growing number of experiments which have successfully demonstrated the clinical potential and safety of small RNAs for combatting diseases ranging from viral infections to cancer as well as neurodegenerative disorders.[41] In 2004, the first Investigational New Drug applications for siRNA were filed in the United States with the Food and Drug Administration; it was intended as a therapy for age-related macular degeneration.[39] RNA silencing in vitro and in vivo has been accomplished by creating triggers (nucleic acids that induce RNAi) either via expression in viruses or synthesis of oligonucleotides.[42] Optimistically many studies indicate that small RNA-based therapies may offer novel and potent weapons against pathogens and diseases where small molecule/pharmacologic and vaccine/biologic treatments have failed or proved less effective in the past.[40] However, it is also warned that the design and delivery of small RNA effector molecules should be carefully considered in order to ensure safety and efficacy.

The role of RNA silencing in therapeutics, clinical medicine, and diagnostics is a fast developing area. A report has been summarized below to highlight the many clinical domains in which RNA silencing is playing an increasingly important role, chief among them are ocular and retinal disorders, cancer, kidney disorders, LDL lowering, and antiviral.[43] The following table displays a listing of RNAi based therapy currently in various phases of clinical trials. The status of these trials can be monitored on the ClinicalTrials.gov website, a service of the National Institutes of Health (NIH).[44] Of note are treatments currently available for ocular and retinal disorders. Both drugs being tested against ocular macular degeneration, AGN211745 (Allergan) and the bevasiranib (Lucentis) have completed their clinical trial cycles, and have now been on the market for the last couple of years. The SYL040012 drug against glaucoma, a condition of ocular hypertension, has since completed its clinical trial phase, and is probably now in use. Also cancer treatment applying the SPC2996 drug against chronic lymphocytic leukemia appears to have completed clinical trials. The Atu027 drug against advanced, recurrent or metastatic solid malignancies appears to have completed clinical trials. Finally, the SPC3649 drug, fighting the Hepatitis C virus, has also completed clinical trials.

Clinical Domain Drug Indication Target
Ocular and retinal disorders TD101 Pachyonychia congenita Keratin 6A N171K mutant
Ocular and retinal disorders QPI-1007 Non-arteritic anterior ischaemic optic neuropathy Caspase 2
Ocular and retinal disorders AGN211745 Age-related macular degeneration, choroidal neovascularization VEGFR1
Ocular and retinal disorders PF-655 Diabetic macular oedema, age-related macular degeneration RTP801
Ocular and retinal disorders SYL040012 Glaucoma β2 adrenergic receptor
Ocular and retinal disorders Bevasiranib Diabetic macular oedema VEGF
Ocular and retinal disorders Bevasiranib Macular degeneration VEGF
Cancer CEQ508 Familial adenomatous polyposis β-catenin
Cancer ALN-PLK1 Liver tumor PLK1
Cancer FANG Solid tumor Furin
Cancer CALAA-01 Solid tumor RRM2
Cancer SPC2996 chronic lymphocytic leukemia BCL-2
Cancer ALN-VSP02 Solid tumor VEGF, kinesin spindle protein
Cancer NCT00672542 Metastatic melanoma LMP2, LMP7, and MECL1
Cancer Atu027 Solid malignancies PKN3
Kidney disorders QPI-1002/I5NP Acute kidney injury p53
Kidney disorders QPI-1002/I5NP Graft dysfunction kidney transplant p53
Kidney disorders QPI-1002/I5NP Kidney injury acute renal failure p53
LDL lowering TKM-ApoB Hypercholesterolaemia APOB
LDL lowering PRO-040,201 Hypercholesterolaemia APOB
Antiviral SPC3649 Hepatitis C virus miR-122
Antiviral pHIV7-shI-TAR-CCR5RZ HIV HIV Tat protein, HIV TAR RNA, human CCR5
Antiviral ALN-RSV01 RSV RSV nucleocapsid
Antiviral ALN-RSV01 RSV in lung transplant patients RSV nucleocapsid

Main challenge[edit]

As with conventional manufactured drugs, the main challenge in developing successful offshoots of the RNAi-based drugs is the precise delivery of the RNAi triggers to where they are needed in the body. The reason that the ocular macular degeneration antidote was successful sooner than the antidote with other diseases is that the eyeball is almost a closed system, and the serum can be injected with a needle exactly where it needs to be. The future successful drugs will be the ones who are able to land where needed, probably with the help of nanobots. Below is a rendition of a table[42] that shows the existing means of delivery of the RNAi triggers.

Species/formulation Packaging capacity Applications & considerations
Viral vector
Adenovirus Usually < 10 Kb dsDNA vector with large packaging capacity, transient expression, highly immunogenic
Adeno-associated virus (AAV) ~4.5Kb ssDNA vector, small packaging capacity, mildly immunogenic, lasting expression in non-dividing cells, capsid pseudotyping/engineering facilitates specific cell-targeting
Lentivirus Up to 13.5 Kb RNA vector, integration competent and incompetent forms available, less immunogenic than adenovirus or AAV, envelope pseudo typing facilitates cell targeting, clinical production more difficult than for adenovirus or AAV
Herpes simplexvirus 150 Kb DNA vector, episomal, lasting expression, immunogenic
Bacterial vector species (bacterial minicells can carry plasmids, siRNAs or drugs)
Escherichis coli, S. Typhymurium Delivery of short hairpin RNA or siRNA to gut tissue
Non-viral formulations
Nanoparticle Self-assembling, may target specific receptors, requires technical expertise to prepare
Stable nucleic acid lipid particle (SNALP) Stable for systemic delivery, broad cell-tye delivery
Aptamer Targeting of specific receptors, requires sophisticated screening to develop
Cholesterol Stable for systemic delivery, broad cell-type delivery

Laboratory[edit]

The scientific community has been quick to harness RNA silencing as a research tool. The strategic targeting of mRNA can provide a large amount of information about gene function and its ability to be turned on and off. Induced RNA silencing can serve as a controlled method for suppressing gene expression. Since the machinery is conserved across most eukaryotes, these experiments scale well to a range of model organisms.[45] In practice, expressing synthetic short hairpin RNAs can be used to reach stable knock-down.[46] If promoters can be made to express these designer short hairpin RNAs, the result is often potent, stable, and controlled gene knock-down in both in vitro and in vivo contexts.[47] Short hairpin RNA vector systems can be seen as roughly analogous in scope to using cDNA overexpression systems.[48] Overall, synthetic and natural small RNAs have proven to be an important tool for studying gene function in cells as well as animals.[49]

Bioinformatics approaches to identify small RNAs and their targets have returned several hundred, if not thousands of, small RNA candidates predicted to affect gene expression in plants, C. elegans, D. melanogaster, zebrafish, mouse, rat, and human.[50] These methods are largely directed to identifying small RNA candidates for knock-out experiments but may have broader applications. One bioinformatics approach evaluated sequence conservation criteria by filtering seed complementary target-binding sites. The cited study predicted that approximately one third of mammalian genes were to be regulated by, in this case, miRNAs.[51]

See also[edit]

References[edit]

  1. ^ a b Fire, A; Xu, S; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC (Feb 19, 1998). "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.". Nature 391 (6669): 806–11. doi:10.1038/35888. PMID 9486653. 
  2. ^ Meister, G; Tuschl, T (Sep 16, 2004). "Mechanisms of gene silencing by double-stranded RNA.". Nature 431 (7006): 343–9. doi:10.1038/nature02873. PMID 15372041. 
  3. ^ a b Gunawardane, LS; Saito, K; Nishida, KM; Miyoshi, K; Kawamura, Y; Nagami, T; Siomi, H; Siomi, MC (Mar 16, 2007). "A slicer-mediated mechanism for repeat-associated siRNA 5' end formation in Drosophila.". Science 315 (5818): 1587–90. doi:10.1126/science.1140494. PMID 17322028. 
  4. ^ a b c d Moazed, D (Jan 22, 2009). "Small RNAs in transcriptional gene silencing and genome defence.". Nature 457 (7228): 413–20. doi:10.1038/nature07756. PMID 19158787. 
  5. ^ Pickford, AS; Cogoni, C (May 2003). "RNA-mediated gene silencing.". Cellular and molecular life sciences : CMLS 60 (5): 871–82. doi:10.1007/s00018-003-2245-2. PMID 12827277. 
  6. ^ a b c Tijsterman, M; Ketting, RF; Plasterk, RH (2002). "The genetics of RNA silencing.". Annual review of genetics 36: 489–519. doi:10.1146/annurev.genet.36.043002.091619. PMID 12429701. 
  7. ^ Malecová, B; Morris, KV (April 2010). "Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs.". Current opinion in molecular therapeutics 12 (2): 214–22. PMID 20373265. 
  8. ^ a b MEISTER, G. (1 March 2004). "Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing". RNA 10 (3): 544–550. doi:10.1261/rna.5235104. PMC 1370948. PMID 14970398. 
  9. ^ Zhou, H; Hu, H; Lai, M (December 2010). "Non-coding RNAs and their epigenetic regulatory mechanisms.". Biology of the cell / under the auspices of the European Cell Biology Organization 102 (12): 645–55. doi:10.1042/BC20100029. PMID 21077844. 
  10. ^ Ding SW (2000). "RNA silencing.". Curr Opin Biotechnol 11 (2): 152–6. doi:10.1016/s0958-1669(00)00074-4. PMID 10753772. 
  11. ^ Susi P, Hohkuri M, Wahlroos T, Kilby NJ (2004). "Characteristics of RNA silencing in plants: similarities and differences across kingdoms.". Plant Mol Biol 54 (2): 157–74. doi:10.1023/B:PLAN.0000028797.63168.a7. PMID 15159620. 
  12. ^ a b Baulcombe D (2004). "RNA silencing in plants.". Nature 431 (7006): 356–63. doi:10.1038/nature02874. PMID 15372043. 
  13. ^ Baulcombe D (2005). "RNA silencing.". Trends Biochem Sci 30 (6): 290–3. doi:10.1016/j.tibs.2005.04.012. PMID 15950871. 
  14. ^ a b c d e f Meister, G.; Tuschl, T. (2004), "[PDF] from blatny.com", Nature 431 (7006): 343–349, retrieved 2011-02-08 
  15. ^ Matzke, MA; Birchler, JA (January 2005). "RNAi-mediated pathways in the nucleus.". Nature Reviews Genetics 6 (1): 24–35. doi:10.1038/nrg1500. PMID 15630419. 
  16. ^ Voinnet, Olivier (10 February 2005). "Induction and suppression of RNA silencing: insights from viral infections". Nature Reviews Genetics 6 (3): 206–220. doi:10.1038/nrg1555. 
  17. ^ Grewal, SI; Rice, JC (June 2004). "Regulation of heterochromatin by histone methylation and small RNAs.". Current opinion in cell biology 16 (3): 230–8. doi:10.1016/j.ceb.2004.04.002. PMID 15145346. 
  18. ^ Poy, MN; Eliasson, L; Krutzfeldt, J; Kuwajima, S; Ma, X; Macdonald, PE; Pfeffer, S; Tuschl, T; Rajewsky, N; Rorsman, P; Stoffel, M (Nov 11, 2004). "A pancreatic islet-specific microRNA regulates insulin secretion.". Nature 432 (7014): 226–30. doi:10.1038/nature03076. PMID 15538371. 
  19. ^ Eccleston, Alex; Angela K. Eggleston (2004). "RNA Interference". Nature 431 (7006): 338. 
  20. ^ a b Eggleston, Angela K. (22 January 2009). "RNA silencing". Nature 457 (7228): 395–395. doi:10.1038/457395a. 
  21. ^ Takeshita, F; Ochiya, T (August 2006). "Therapeutic potential of RNA interference against cancer.". Cancer science 97 (8): 689–96. doi:10.1111/j.1349-7006.2006.00234.x. PMID 16863503. 
  22. ^ Dykxhoorn, DM; Novina, CD; Sharp, PA (June 2003). "Killing the messenger: short RNAs that silence gene expression.". Nature Reviews Molecular Cell Biology 4 (6): 457–67. doi:10.1038/nrm1129. PMID 12778125. 
  23. ^ Hammond, SM; Caudy, AA; Hannon, GJ (February 2001). "Post-transcriptional gene silencing by double-stranded RNA.". Nature Reviews Genetics 2 (2): 110–9. doi:10.1038/35052556. PMID 11253050. 
  24. ^ Bühler, M (April 2009). "RNA turnover and chromatin-dependent gene silencing.". Chromosoma 118 (2): 141–51. doi:10.1007/s00412-008-0195-z. PMID 19023586. 
  25. ^ Gonzalez, S; Pisano, DG; Serrano, M (Aug 15, 2008). "Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs.". Cell cycle (Georgetown, Tex.) 7 (16): 2601–8. doi:10.4161/cc.7.16.6541. PMID 18719372. 
  26. ^ Kim, JK; Gabel, HW; Kamath, RS; Tewari, M; Pasquinelli, A; Rual, JF; Kennedy, S; Dybbs, M; Bertin, N; Kaplan, JM; Vidal, M; Ruvkun, G (May 20, 2005). "Functional genomic analysis of RNA interference in C. elegans.". Science 308 (5725): 1164–7. doi:10.1126/science.1109267. PMID 15790806. 
  27. ^ Bühler, M; Moazed, D (November 2007). "Transcription and RNAi in heterochromatic gene silencing.". Nature structural & molecular biology 14 (11): 1041–8. doi:10.1038/nsmb1315. PMID 17984966. 
  28. ^ Dombroski, BA; Feng, Q; Mathias, SL; Sassaman, DM; Scott, AF; Kazazian HH, Jr; Boeke, JD (July 1994). "An in vivo assay for the reverse transcriptase of human retrotransposon L1 in Saccharomyces cerevisiae.". Molecular and Cellular Biology 14 (7): 4485–92. PMC 358820. PMID 7516468. 
  29. ^ Svoboda, P (2008). "RNA silencing in mammalian oocytes and early embryos.". Current topics in microbiology and immunology 320: 225–56. doi:10.1007/978-3-540-75157-1_11. PMID 18268847. 
  30. ^ Ghildiyal, M; Seitz, H; Horwich, MD; Li, C; Du, T; Lee, S; Xu, J; Kittler, EL; Zapp, ML; Weng, Z; Zamore, PD (May 23, 2008). "Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells.". Science 320 (5879): 1077–81. doi:10.1126/science.1157396. PMID 18403677. 
  31. ^ Filipowicz, W; Jaskiewicz, L; Kolb, FA; Pillai, RS (June 2005). "Post-transcriptional gene silencing by siRNAs and miRNAs.". Current opinion in structural biology 15 (3): 331–41. doi:10.1016/j.sbi.2005.05.006. PMID 15925505. 
  32. ^ Bao, N; Lye, KW; Barton, MK (November 2004). "MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome.". Developmental cell 7 (5): 653–62. doi:10.1016/j.devcel.2004.10.003. PMID 15525527. 
  33. ^ Zeng, Yan; Yi, Rui; Cullen, Bryan R (25 November 2004). "Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha". The EMBO Journal 24 (1): 138–148. doi:10.1038/sj.emboj.7600491. PMC 544904. PMID 15565168. 
  34. ^ Irvine, DV; Zaratiegui, M; Tolia, NH; Goto, DB; Chitwood, DH; Vaughn, MW; Joshua-Tor, L; Martienssen, RA (Aug 25, 2006). "Argonaute slicing is required for heterochromatic silencing and spreading.". Science 313 (5790): 1134–7. doi:10.1126/science.1128813. PMID 16931764. 
  35. ^ Klattenhoff, C; Theurkauf, W (January 2008). "Biogenesis and germline functions of piRNAs.". Development (Cambridge, England) 135 (1): 3–9. doi:10.1242/dev.006486. PMID 18032451. 
  36. ^ Ishizu, H; Siomi, H; Siomi, MC (Nov 1, 2012). "Biology of PIWI-interacting RNAs: new insights into biogenesis and function inside and outside of germlines.". Genes & Development 26 (21): 2361–73. doi:10.1101/gad.203786.112. PMID 23124062. 
  37. ^ Matthew P Scott; Lodish, Harvey F.; Arnold Berk; Kaiser, Chris; Monty Krieger; Anthony Bretscher; Hidde Ploegh; Angelika Amon (2012). Molecular Cell Biology. San Francisco: W. H. Freeman. ISBN 1-4292-3413-X. 
  38. ^ Voorhoeve, PM; Agami, R (January 2003). "Knockdown stands up.". Trends in Biotechnology 21 (1): 2–4. doi:10.1016/S0167-7799(02)00002-1. PMID 12480342. 
  39. ^ a b Karagiannis, Tom C; El-Osta, Assam (13 May 2005). "RNA interference and potential therapeutic applications of short interfering RNAs". Cancer Gene Therapy 12 (10): 787–795. doi:10.1038/sj.cgt.7700857. 
  40. ^ a b Kim, Daniel H.; Rossi, John J. (1 March 2007). "Strategies for silencing human disease using RNA interference". Nature Reviews Genetics 8 (3): 173–184. doi:10.1038/nrg2006. 
  41. ^ Stevenson, Mario (21 October 2004). "Therapeutic Potential of RNA Interference". New England Journal of Medicine 351 (17): 1772–1777. doi:10.1056/NEJMra045004. 
  42. ^ a b Davidson, Beverly L.; McCray, Paul B. (1 May 2011). "Current prospects for RNA interference-based therapies". Nature Reviews Genetics 12 (5): 329–340. doi:10.1038/nrg2968. PMID 21499294. 
  43. ^ Davidson, BL; McCray PB, Jr (May 2011). "Current prospects for RNA interference-based therapies.". Nature Reviews Genetics 12 (5): 329–40. doi:10.1038/nrg2968. PMID 21499294. 
  44. ^ http://clinicaltrials.gov
  45. ^ Zeng, Y; Wagner, EJ; Cullen, BR (June 2002). "Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells.". Molecular Cell 9 (6): 1327–33. doi:10.1016/s1097-2765(02)00541-5. PMID 12086629. 
  46. ^ Paddison, PJ; Caudy, AA; Bernstein, E; Hannon, GJ; Conklin, DS (Apr 15, 2002). "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.". Genes & Development 16 (8): 948–58. doi:10.1101/gad.981002. PMID 11959843. 
  47. ^ Dickins, RA; Hemann, MT; Zilfou, JT; Simpson, DR; Ibarra, I; Hannon, GJ; Lowe, SW (November 2005). "Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.". Nature Genetics 37 (11): 1289–95. doi:10.1038/ng1651. PMID 16200064. 
  48. ^ Rigó, G; Papdi, C; Szabados, L (2012). "Transformation using controlled cDNA overexpression system.". Methods in molecular biology (Clifton, N.J.) 913: 277–90. doi:10.1007/978-1-61779-986-0_19. PMID 22895767. 
  49. ^ Silva, JM; Li, MZ; Chang, K; Ge, W; Golding, MC; Rickles, RJ; Siolas, D; Hu, G; Paddison, PJ; Schlabach, MR; Sheth, N; Bradshaw, J; Burchard, J; Kulkarni, A; Cavet, G; Sachidanandam, R; McCombie, WR; Cleary, MA; Elledge, SJ; Hannon, GJ (November 2005). "Second-generation shRNA libraries covering the mouse and human genomes.". Nature Genetics 37 (11): 1281–8. doi:10.1038/ng1650. PMID 16200065. 
  50. ^ Berezikov, E; Guryev, V; van de Belt, J; Wienholds, E; Plasterk, RH; Cuppen, E (Jan 14, 2005). "Phylogenetic shadowing and computational identification of human microRNA genes.". Cell 120 (1): 21–4. doi:10.1016/j.cell.2004.12.031. PMID 15652478. 
  51. ^ Lewis, BP; Burge, CB; Bartel, DP (Jan 14, 2005). "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.". Cell 120 (1): 15–20. doi:10.1016/j.cell.2004.12.035. PMID 15652477. 

External links[edit]

  • Nature Reviews animation explaining the mechanism of RNAi can be found here.